STOPDAPT-3: an aspirin-free antithrombotic strategy for percutaneous coronary intervention

Reported from ESC Congress 2023

Aaysha Cader interviews Masahiro Natsuaki about the design and results of the STOPDAPT-3 trial which he presented during the ESC Congress 2023 in Amsterdam.

Prasugrel monotherapy after PCI with drug-eluting stents was not superior to dual-antiplatelet therapy (DAPT) for major bleeding but was non-inferior for cardiovascular events in patients with acute coronary syndrome or high bleeding risk.